Inventor · disambiguated record
Klaus Kopka
Also filed as: KOPKA KLAUS
17 granted patents·14 pending applications·87 citations·filing 2003–2024
93Inventor score
Files withDEUTSCHES KREBSFORSCH17BREMER CHRISTOPH2KOPKA KLAUS2NOVARTIS AG2ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH1
Top patents by PatentIndex Score
31 records- 0196US11951190B2Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2021·Granted Apr 9, 2024·4 cites·62 claims
- 0296US11931430B2Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2020·Granted Mar 19, 2024·5 cites·15 claims
- 0396US11045564B2Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2019·Granted Jun 29, 2021·10 cites·15 claims
- 0496US10398791B2Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2018·Granted Sep 3, 2019·22 cites·30 claims
- 0594US10471160B2Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2018·Granted Nov 12, 2019·16 cites·28 claims
- 0693US10815200B218F—tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancerDEUTSCHES KREBSFORSCH·Filed 2018·Granted Oct 27, 2020·8 cites·8 claims
- 0791US10016519B218F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2017·Granted Jul 10, 2018·8 cites·18 claims
- 0890US2024382631A1Use of labeled inhibitors of prostate specific membrane antigen (psma), as agents for the treatment of prostate cancerNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0989US2024350680A1Labeled inhibitors of prostate specific membrane antigen (psma) as agents for the treatment of prostate cancerNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1083US12054458B218F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancerDEUTSCHES KREBSFORSCH·Filed 2023·Granted Aug 6, 2024·0 cites·12 claims
- 1181US11020493B2Double-labeled probe for molecular imaging and use thereofDEUTSCHES KREBSFORSCH·Filed 2019·Granted Jun 1, 2021·1 cites·7 claims
- 1279US11452786B2Double-labeled probe for molecular imaging and use thereofDEUTSCHES KREBSFORSCH·Filed 2018·Granted Sep 27, 2022·1 cites·66 claims
- 1374US2025057993A1Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancersUNIV HEIDELBERG·Filed 2024·Application pending·0 cites
- 1471US10406246B2Double-labeled probe for molecular imaging and use thereofDEUTSCHES KREBSFORSCH·Filed 2014·Granted Sep 10, 2019·1 cites·11 claims
- 1571US2019336622A1Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2019·Application pending·0 cites
- 1668US12156920B2Double-labeled probe for molecular imaging and use thereofDEUTSCHES KREBSFORSCH·Filed 2022·Granted Dec 3, 2024·0 cites·22 claims
- 1768US9023318B2Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereofCHEN GANG·Filed 2013·Granted May 5, 2015·1 cites·6 claims
- 1868US2021053922A118f - tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancerDEUTSCHES KREBSFORSCH·Filed 2020·Application pending·0 cites
- 1965US8231858B2Diagnostic imaging agents with MMP inhibitory activitySTOREY ANTHONY·Filed 2004·Granted Jul 31, 2012·9 cites·8 claims
- 2064US8212058B2Fluorescent photoprobe for the imaging of endothelin receptorsBREMER CHRISTOPH·Filed 2006·Granted Jul 3, 2012·1 cites·7 claims
- 2162US2025144253A13-((3-([1,1'-biphenyl]-3-ylmethoxy)phenoxy)methyl)benzonitrile derivatives and the use thereofHELMHOLTZ ZENTRUM DRESDEN·Filed 2022·Application pending·0 cites
- 2262US2016228587A1Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2016·Application pending·0 cites
- 2361US2021393809A1Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancersUNIV HEIDELBERT·Filed 2019·Application pending·0 cites
- 2450US2023406847A1Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocksABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH·Filed 2021·Application pending·0 cites
- 2548US2022324898A1Prostate specific membrane antigen (psma) ligands comprising an amylase cleavable linkerDEUTSCHES KREBSFORSCH·Filed 2020·Application pending·0 cites
- 2648US2013149239A15-pyrrolidinylsulfonyl-isatin derivativesUNIVERSITATSKLINIKUM MUNSTER·Filed 2012·Application pending·0 cites
- 2746US8440841B25-pyrrolidinylsulfonyl isatin derivativesKOPKA KLAUS·Filed 2005·Granted May 14, 2013·0 cites·3 claims
- 2845US11638765B2Double-labeled probe for molecular imaging and use thereofDEUTSCHES KREBSFORSCH·Filed 2018·Granted May 2, 2023·0 cites·41 claims
- 2942US2006120956A1Imaging agents comprising barbituric acid derivativesKOPKA KLAUS·Filed 2003·Application pending·0 cites
- 3040US2013004430A1Fluorescent photoprobe for the imaging of endothelin receptorsBREMER CHRISTOPH·Filed 2012·Application pending·0 cites
- 3130US2012282180A1Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents ThereofKOLB HARTMUTH C·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Klaus Kopka files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →